Risperidona

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Risperidona

Property Description
Active ingredient Risperidone
Form Tablet, Oral Solution, Injectable Suspension
Pharmacological class Second-Generation Antipsychotic (SGA)
Common use Management of severe mental disorders (Psychosis)
Origin Synthetic compound (Benzisoxazole derivative)

What Type of Medicine is Risperidona?

Risperidona is a modern psychopharmacological agent containing the active ingredient Risperidone, which is classified as an antipsychotic agent intended for the management of severe mental disorders. As a synthetic compound derived from the benzisoxazole chemical group, it is specifically designated a Second-generation antipsychotic (SGA), or atypical antipsychotic. This designation reflects the drug's balanced pharmacological profile and its advancement over older treatments. The distinctive feature of Risperidone is its early clinical recognition for managing acute episodes in certain patient populations.


How is Risperidone Classified Pharmacologically?

Pharmacologically, Risperidone is defined as a Serotonin-dopamine antagonist (SDA), which is the key to its unique mechanism of effect. This means the compound exerts a dual physiological action by engaging specific receptor-binding affinity to block two types of brain receptors: the Dopamine D₂ receptor and the Serotonin 5HT₂ₑ receptor. The simultaneous D₂ blockade and 5HT₂ₑ blockade define the medicine's core efficacy in the central nervous system. This action is clinically recognized for stabilizing the neurotransmitter signaling patterns often disrupted in psychosis.


Available Forms and General Purpose

Risperidona is manufactured as a single active ingredient product in various dosage form(s) to ensure patient flexibility, including the standard tablet, an oral solution, and a specialized long-acting injectable suspension. The availability of an oral solution is a differentiating factor, making precise titration and administration simpler for certain patients with mental disorders. The medicine's overarching therapeutic purpose is to help restore clearer thinking and improve emotional regulation by modulating the core neurochemical imbalances.

Regulatory References

  1. Risperidone Mechanism of Action (NIH)

What side effects are possible with Risperidona?

Possible Side Effects and Safety Information

Official Safety Warnings and Limitations

Risperidona (Risperidone) carries a Boxed Warning regarding increased mortality risk in elderly patients with dementia-related psychosis. This medication is not approved for the treatment of this condition. Furthermore, this population is at an increased risk of Cerebrovascular Adverse Reactions (e.g., stroke, transient ischemic attack).

Other serious, clinically significant adverse reactions include Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex requiring immediate discontinuation, and Tardive Dyskinesia (TD), a syndrome of potentially irreversible, involuntary movements. Serious metabolic changes, such as Hyperglycemia and Diabetes Mellitus, have been reported, necessitating regular monitoring of blood glucose levels and weight.

Common Adverse Reactions

The most commonly reported adverse reactions often involve the nervous system and gastrointestinal tract. These may include Extrapyramidal Symptoms (EPS) (such as parkinsonism, akathisia, dystonia, and tremor), sedation, dizziness, anxiety, nausea, vomiting, constipation, dry mouth, and increased appetite leading to weight gain.

Other Safety Considerations

  • Hyperprolactinemia: Risperidona can cause sustained elevation of prolactin levels, which may lead to adverse effects like amenorrhea, galactorrhea, gynecomastia, and sexual dysfunction.
  • Orthostatic Hypotension: A drop in blood pressure upon standing is possible, especially during initial dosing, increasing the risk of falls.
  • Hematologic Risk: Cases of leukopenia, neutropenia, and agranulocytosis have been reported; patients with a history of low white blood cell count require frequent monitoring.
  • Seizures and Body Temperature Regulation: The medication should be used with caution in patients with a history of seizures. It may also impair the body's ability to regulate temperature, requiring caution in extreme heat or cold.

Overdose and Emergency Response

Overdose: When to Seek Immediate Medical Help

Overdose with risperidone primarily results in an exaggeration of the medicine's expected effects, affecting both the central nervous system (CNS) and the cardiovascular system. Due to the potential for serious complications, any suspected overdose requires prompt medical evaluation.

Documented Overdose Symptoms

The most commonly reported effects of overdose include drowsiness, pronounced sedation, tachycardia (fast heart rate), and hypotension (low blood pressure). Individuals may also experience extrapyramidal symptoms (involuntary muscle movements, such as tremor or spasms), convulsions, or a prolonged QT interval, which can be life-threatening for vulnerable patients.

Overdose has been reported in children, sometimes due to accidental administration errors, with symptoms like extrapyramidal movements being a concern even at lower accidental doses. The risk of potentially life-threatening cardiovascular and CNS events, particularly seizures, is a key concern.

Required Emergency Actions

If you suspect an overdose, immediately call emergency services or a poison control center. Urgent medical attention is necessary if the person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. There is no specific antidote for risperidone overdose; management focuses on supportive and symptomatic care, including maintaining an adequate airway, monitoring heart rhythm and vital signs, and treating low blood pressure with appropriate measures.

Therapeutic Uses of Risperidona

Risperidona is commonly used in situations involving certain distressing symptoms across three primary therapeutic domains. The medication is relevant for easing symptoms associated with Schizophrenia, acute manic or mixed episodes of Bipolar I Disorder, and disruptive behavioral problems linked to Autistic Disorder.


Applied in Contexts of Disturbed Thought and Perception

Risperidona is applied in addressing conditions like Schizophrenia, focusing on symptoms that create noticeable functional strain, such as hallucinations, delusions, and disorganized thinking. It helps patients cope more steadily with these disruptive symptom manifestations during acute episodes and long-term phases.


Relevant for Acute Mood Swings and Agitation

Risperidona is relevant in contexts involving heightened systemic burden, specifically applied in addressing acute manic or mixed episodes associated with Bipolar I Disorder. It assists with symptoms related to heightened physiological activity, including agitation and irritable mood. This contributes to improved comfort by supporting the patient during episodes of heightened discomfort.


Supporting Management of Behavioral Problems

The treatment is commonly used in situations where additional symptomatic support is needed to address disruptive behavioral problems in children and adolescents with Autistic Disorder. It is relevant for easing symptoms such as aggression and self-injurious behavior. This provides support that helps ease the overall symptom burden and supports general well-being during symptomatic phases.


Quick Fact: Relief for Behavioral Disruptions

Quick Fact: Relief for Irritability and Aggression. The medication is used when groups of symptoms, particularly aggression and self-injurious behavior in younger patients with Autistic Disorder, appear suddenly or fluctuate and require supportive management.

Regulatory References

  1. NIH MedlinePlus Drug Information Overview

Eligibility and Restrictions for Use

Eligibility to Use Risperidona: Official Regulatory Information

Contraindications and Restrictions

Risperidona is contraindicated for any individual with a known hypersensitivity to the drug (risperidone), its main active metabolite (paliperidone), or any other component in the formulation.

The medication is not approved for the treatment of elderly patients with dementia-related psychosis due to an observed increased risk of death and cerebrovascular adverse events, including stroke. This is a critical regulatory restriction.

Age and Condition Considerations

Population Group Eligibility Status (Regulatory Basis)
Dementia-Related Psychosis Not Approved (Increased mortality risk)
Severe Renal/Hepatic Impairment Use requires a lower starting dose and slower titration.
Schizophrenia Not established for use in children under 13 years of age.
Bipolar Mania Not established for use in children under 10 years of age.
Autistic Irritability Not established for use in children under 5 years of age.

Pregnancy and Lactation

Newborns exposed to risperidona during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms. Risperidona and its metabolite are excreted in human milk, and nursing mothers are generally advised against breastfeeding while on this treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail the required management of Risperidona when used alongside specific medicines and products. The interaction profile is primarily defined by the drug's metabolism and its effects on the central nervous and cardiovascular systems.


Documented Interacting Substances

Interaction Type Examples of Interacting Medicines or Products
Enzyme Inhibitors Fluoxetine, Paroxetine (can increase Risperidona levels)
Enzyme Inducers Carbamazepine (can decrease Risperidona levels)
CNS Depressants Alcohol, other psychoactive agents
Hypotensive Agents Specific antihypertensive drugs
Specific Agents Levodopa, Cimetidine, Ranitidine, Clozapine

Practical Interaction Constraints

When Risperidona is co-administered with strong inhibitors of the CYP 2D6 enzyme, a reduction in the initial dosing may be required due to increased plasma concentrations of the active antipsychotic fraction. Conversely, co-administration with strong enzyme inducers (such as Carbamazepine) may necessitate an increase in the Risperidona dose because the inducer can decrease the plasma concentration of the active fraction. Alcohol must be avoided due to the risk of enhanced central nervous system (CNS) depressant effects. Caution is necessary with co-administration of antihypertensive medicines due to the potential for additive hypotensive effects. The liquid formulation of Risperidona must not be mixed with tea or cola.

Mechanism of Action

Stabilizing Central Neurotransmitter Pathways

Risperidone's primary mechanism is its action as a Serotonin-Dopamine Antagonist (SDA), achieved by blocking both the Dopamine D2 and Serotonin 5-HT2A receptors with high affinity. This dual blockade is applied within central neural circuits, primarily the mesolimbic and frontal cortical pathways, to modulate and adjust heightened or dysregulated signaling patterns.


️ Balancing Motor Control Signaling

Antagonism of the 5-HT2A receptor acts as a molecular modulator for the motor system, specifically in the nigrostriatal pathway. This 5-HT2A mechanism supports a functional increase in dopamine release in the motor area, which results in the modulation of dopamine signaling that counters the D2 blockade effect on these circuits.


Influencing Autonomic and Arousal Systems

Secondary binding occurs at other regulatory targets, notably the adrenergic alpha1 receptors and histamine H1 receptors. Antagonism of alpha1 receptors affects the autonomic nervous system and vascular tone, while H1 antagonism affects central histaminergic arousal pathways.

Dosage and Administration Information

Risperidona is administered through two primary pathways: the oral route (tablets, oral solution, and orally disintegrating tablets) and the intramuscular (IM) route for long-acting injectable suspensions. The long-acting injection must be administered deeply into the muscle by a healthcare professional and is specifically instructed not to be administered intravenously.

Oral treatment regimens for adults often begin with a low dose, such as 2 mg per day for Schizophrenia, which is then gradually adjusted over time. The daily dose may be taken once daily or in divided doses and can be consumed with or without food. Titration, or dose increases, must adhere to prescribed intervals, typically occurring no sooner than every 24 hours.

The long-acting injectable forms follow an intermittent schedule, administered either every 2 weeks or monthly. When initiating the bi-weekly long-acting injection, the instructions mandate that the patient continue taking an oral antipsychotic concurrently for the first three weeks to ensure continuous therapeutic coverage.

Special dosing rules apply to certain groups. Older adults and patients with renal or hepatic impairment must begin treatment with a lower initial dose, commonly 0.5 mg twice daily, and follow a slower titration schedule. The oral solution can be mixed with several common beverages, including water and coffee, but instructions specify it should not be mixed with cola or tea.

Recent Clinical Evidence

Recent Clinical Evidence

Evaluating the Intervention’s Potential Role in Symptom Management

Studies have explored whether the intervention is associated with changes in symptoms and clinical scores relevant to its indicated uses. Studies have focused on the clinical observations reported after intervention, including symptoms and functional scores. Preliminary findings have been reported in smaller, observational cohorts.

  • Symptom Reduction: Research has assessed whether the intervention is associated with a reduction in symptom severity over specified observation periods. Findings across different studies have been evaluated regarding the consistency of this association.
  • Functional Improvements: Studies have also assessed whether the intervention is associated with improvements in daily functioning and quality of life measures in individuals with the relevant conditions.

Findings in Specific Chronic Conditions

Studies have focused on whether the intervention may have a role in the management of chronic conditions. The evidence remains limited in some areas and is often drawn from small-scale, non-randomized studies when examining specific long-term outcomes.

Tolerability and Safety Profile

Studies have reported that the tolerability of the intervention has been evaluated in different patient populations. Findings included reports of common side effects, which are detailed in the full safety information section.

  • Long-Term Data: Long-term follow-up studies have evaluated whether the intervention is associated with changes in long-term health outcomes. Data spanning periods beyond two years remains scarce for certain study parameters.
  • Combined Treatment Research: Studies have examined the outcomes of combined treatment regimens, such as using the intervention alongside psychosocial support. Some studies have compared the time course of changes in specific markers associated with the intervention versus other treatments.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE) Guideline: Psychosis and schizophrenia in adults: prevention and management (NG226)

Frequently Asked Questions (FAQ)

Common questions about Risperidona (FAQ)


Q: How long does it usually take to feel the effects of Risperidona?

According to the official product information, the time it takes to observe the full therapeutic effect can vary. While some effects from the oral form may start to appear in a few days, the full therapeutic effect may be observed over a period of several weeks. For the long-acting injectable form, full clinical effects from a dose change should not be anticipated any sooner than 3 weeks after the injection is administered.


Q: Are there any common side effects people report when starting Risperidona?

Regulatory documents indicate that the risk of certain effects may occur particularly during the start of treatment. Specifically, Orthostatic Hypotension, a drop in blood pressure when standing that can cause dizziness or fainting, is noted as occurring particularly during the initial dose titration period.


Q: Is it normal to feel dizzy or lightheaded when taking Risperidona?

Official safety information lists dizziness as a common adverse reaction. Feeling lightheaded upon standing may be related to Orthostatic Hypotension, which is a possible adverse reaction where blood pressure drops briefly. This effect is a documented reason for caution when starting the medication.


Q: Can elderly patients use Risperidona safely?

Official regulatory warnings must be followed, as Risperidona is not approved for treating elderly patients with dementia-related psychosis due to an increased risk of death and stroke. For otherwise healthy elderly patients, a specific low starting dose may be indicated to initiate treatment, and an increased susceptibility to adverse effects like Orthostatic Hypotension has been noted.


Q: Is Risperidona safe to use during pregnancy or while breastfeeding (general question)?

Regulatory information advises caution during pregnancy. Exposure during the third trimester carries a risk of the newborn experiencing extrapyramidal (movement) or withdrawal symptoms. Since the medicine and its metabolite are excreted into human milk, official guidance states that nursing mothers are generally advised against breastfeeding while on this treatment.


Q: How is Risperidona usually stopped or tapered off?

Abrupt discontinuation is generally advised against by regulatory guidelines because it may increase the risk of symptoms returning or cause withdrawal symptoms. Treatment discontinuation requires supervision by a healthcare professional, typically involving a gradual dosage reduction (taper) over time.


Q: Are there different forms of Risperidona available (e.g., tablet, liquid)?

Yes, to ensure patient flexibility, Risperidona is manufactured in several forms. These include a standard tablet, an oral solution, an orally disintegrating tablet (ODT), and a long-acting injectable suspension.


Q: Why is it important to have regular check-ups while taking Risperidona?

Regulatory documents require ongoing monitoring for several serious potential adverse effects. This includes monitoring for metabolic changes (like checking blood glucose levels and tracking weight), the risk of Hyperprolactinemia (high prolactin levels), and changes in white blood cell count.


Q: Can Risperidona be used for managing anger or aggression?

The approved indications for Risperidona include the treatment of irritability associated with autistic disorder. Its primary FDA-approved uses are for managing schizophrenia and acute manic or mixed episodes associated with Bipolar I Disorder.


Q: Is Risperidona a type of tranquilizer?

Regulatory documents classify Risperidona as an atypical antipsychotic (or Second-Generation Antipsychotic). This is the designated pharmacological classification for the medicine, rather than the older term 'tranquilizer'.


Q: Does Risperidona help with sleep?

In clinical trials, official information lists both sedation (drowsiness) and insomnia (difficulty sleeping) as common adverse reactions. The medicine is not specifically approved for use as a sleep aid.


Q: Does Risperidona cause weight gain, and if so, how common is it?

Weight gain is listed as a common and significant adverse reaction, often associated with an increased appetite. The official labeling indicates this effect was observed in a notable percentage of patients during clinical trials.


Q: Is it safe to take herbal supplements with Risperidona?

Official sources include warnings regarding the co-administration of certain herbal products due to potential interactions. For instance, St. John's wort may reduce the overall effectiveness of the medicine, and Ginkgo biloba may increase the risk of specific side effects.


Q: What happens if you miss a dose of Risperidona?

Missing a dose carries the risk of a relapse in symptoms. Regulatory guidelines describe procedures for a missed oral dose, which is generally taken as soon as remembered (unless close to the next scheduled dose). Patients should contact their doctor immediately if a long-acting injection has been missed.


Q: Does Risperidona cause changes in appetite?

In clinical trials, increased appetite is listed as a common adverse reaction. This change in appetite is often linked to the possibility of weight gain.


Q: Is it possible for Risperidona to cause high Prolactin levels?

Yes, official safety information indicates that Risperidona can cause Hyperprolactinemia, which is a sustained elevation of prolactin levels. This condition is associated with potential adverse effects such as changes in menstrual cycles, abnormal breast milk production, and sexual dysfunction.


Q: How does Risperidona differ from older antipsychotic drugs?

Risperidona is classified as a Second-Generation Antipsychotic (SGA), also known as an atypical antipsychotic. This classification reflects the drug’s pharmacological profile compared to older, first-generation antipsychotics.


Q: What does official guidance say about using Risperidona with blood pressure medicine?

Regulatory documents include warnings to use caution when co-administered with antihypertensive medicines (blood pressure medicine). This is due to the potential for additive hypotensive effects, meaning the combination may cause an increased lowering of blood pressure.


Q: Do people develop a physical dependence on Risperidona?

Risperidona is not classified as a controlled substance by regulatory bodies, and the official label does not discuss physical dependence. However, abrupt discontinuation is generally discouraged due to the potential for withdrawal symptoms or symptom relapse.


Q: Is Risperidona a controlled substance?

No, Risperidona is not classified as a controlled substance under the Controlled Substances Act (CSA) in the United States. This designation indicates it does not fall into the categories of drugs with specific abuse potential.


Q: Can Risperidona cause sun sensitivity or skin issues?

General skin rash is listed as a possible adverse reaction in official safety data. While a specific warning about photosensitivity (sun sensitivity) is not consistently detailed in the core safety warnings, caution regarding skin exposure is a general consideration with many medications.


Q: Does Risperidona affect sex drive?

Adverse reactions reported in clinical trials include decreased libido and general sexual dysfunction. These effects are sometimes related to the drug's potential for causing increased Prolactin levels.


Q: Is Risperidona used for Bipolar Disorder?

Yes, regulatory documents approve Risperidona for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder. It can be used as a single treatment or as an additional therapy.


Q: Can Risperidona interact with nicotine replacement products?

Official documents caution against the use of central nervous system (CNS) depressants. While nicotine replacement products are not listed as a specific drug constraint, studies have examined the complex interaction between nicotine and risperidone in a research setting.


Q: What are common reasons for discontinuation of Risperidona, according to studies?

Official clinical trial data indicates that the most common adverse reactions that led to patients discontinuing treatment for schizophrenia were agitation and depression.


Q: Is Risperidona prescribed for conditions other than schizophrenia?

Yes, in addition to schizophrenia, Risperidona is approved by regulatory bodies for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder and irritability associated with autistic disorder.


Q: How does Risperidona impact coordination?

The official label notes that the medicine has the potential to impair motor skills and coordination. Adverse reactions that affect movement and coordination include Extrapyramidal Symptoms (EPS) such as parkinsonism, dystonia, and akathisia.

How should Risperidona be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define specific conditions for storing and disposing of risperidone products to ensure stability and public safety. All forms of risperidone must be kept out of the sight and reach of children.


Storage Conditions

Formulation Required Storage Condition
Oral Forms (Tablets/Solution) Store at controlled room temperature (20°C to 25°C), protect from light and moisture, and do not freeze the solution. Keep the solution bottle tightly closed.
Long-Acting Injectable Kit Must be refrigerated (2°C to 8°C). The kit may be stored at room temperature for a maximum of seven days, after which it must be discarded if unused. The suspension must be administered immediately after mixing.

Disposal Instructions

Unused or expired risperidone products should not be disposed of in wastewater or household trash. Disposal must be conducted according to local regulatory requirements for medicinal waste. Needles and syringes used for the long-acting injection must be placed into a puncture-resistant sharps disposal container immediately after use.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Risperidona found in:

A-Z Index: